It is well documented that dysregulation of FGF-FGFR signaling via amplification, point mutation or translocations may have an important role in tumor development and progression. Alterations in FGFRs are associated with a number of human cancers, including lung, myeloma, breast, gastric, colon, bladder, pancreatic, and hepatocellular carcinomas. A growing body of preclinical data demonstrates that inhibition of FGFR signaling can result in antiproliferative and/or pro-apoptic effects, thus confirming the validity of the FGFR/FGFR axis as a potential therapeutic target. The FGFR2 (10q26) FISH probe is optimized to detect copy numbers of the FGFR2 gene region at region 10q26. The Chromosome 10 Satellite Enumeration (SE) probe is included to facilitate chromosome identification.
References: Brooks et al, Clin Cancer Res. 2012; 18:1855. Dutt et al, PLoS ONE 6: e2035.1. Kunii et al, Cancer Res. 2008; 68:2340-8. Liang et al, Clin Cancer Res. 2013; 19:2572. Liao et al, Cancer Res. 2013; 73:5195-205. Weiss et al, Sci Transl Med. 2010; 2:62ra93.